Evaluation of smallpox vaccines using variola neutralization

Journal of General Virology

Volumn 90, Issue 8, 2009, Pages 1962-1966

  Damon, Inger K ^a   Davidson, Whitni B ^a   Hughes, Christine M ^a   Olson, Victoria A ^a   Smith, Scott K ^a   Holman, Robert C ^a   Frey, Sharon E ^b   Newman, Frances ^b   Belshe, Robert B ^b   Yan, Lihan ^c   Karem, Kevin ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; HUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS NEUTRALIZATION; ANIMAL; BLOOD; IMMUNOLOGY; METHODOLOGY; SERODIAGNOSIS; SMALLPOX VIRUS;

VACCINIA VIRUS ANKARA; VARIOLA; VARIOLA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; NEUTRALIZATION TESTS; SMALLPOX VACCINE; VARIOLA VIRUS;

EID: 69449104908     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.010553-0     Document Type: Article

References (22)

1. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
2. Davies, D. H., Liang, X., Hernandez, J. E., Randall, A., Hirst, S., Mu, Y., Romero, K. M., Nguyen, T. T., Kalantari-Dehaghi, M. & other authors (2005a). Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci U S A 102, 547-552.
3. Davies, D. H., McCausland, M. M., Valdez, C., Huynh, D., Hernandez, J. E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P. L., Crotty, S. & other authors (2005b). Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79, 11724-11733.
4. Davies, D. H., Molina, D. M., Wrammert, J., Miller, J., Hirst, S., Mu, Y., Pablo, J., Unal, B., Nakajima-Sasaki, R. & other authors (2007). Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 7, 1678-1686.
5. Davies, D. H., Wyatt, L. S., Newman, F. K., Earl, P. L., Chun, S., Hernandez, J. E., Molina, D. M., Hirst, S., Moss, B. & other authors (2008). Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J Virol 82, 652-663.
6. Fogg, C. N., Americo, J. L., Lustig, S., Huggins, J. W., Smith, S. K., Damon, I., Resch, W., Earl, P. L., Klinman, D. M., Moss, B. & other authors (2007). Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25, 2787-2799.
7. Frey, S. E., Newman, F. K., Cruz, J., Shelton, W. B., Tennant, J. M., Polach, T., Rothman, A. L., Kennedy, J. S., Wolff, M. & other authors (2002). Dose-related effects of smallpox vaccine. N Engl J Med 346, 1275-1280.
8. Frey, S. E., Newman, F. K., Yan, L., Lottenbach, K. R. & Belshe, R. B. (2003). Response to smallpox vaccine in persons immunized in the distant past. JAMA 289, 3295-3299.
9. Frey, S. E., Newman, F. K., Kennedy, J. S., Sobek, V., Ennis, F. A., Hill, H., Yan, L. K., Chaplin, P., Vollmar, J. & other authors (2007). Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25, 8562-8573.
10. Karem, K. L., Reynolds, M., Braden, Z., Lou, G., Bernard, N., Patton, J. & Damon, I. K. (2005). Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 12, 867-872.
11. Lane, J. M. & Goldstein, J. (2003). Adverse events occurring after smallpox vaccination. Semin Pediatr Infect Dis 14, 189-195.
12. Lawrence, S. J., Lottenbach, K. R., Newman, F. K., Buller, R. M., Bellone, C. J., Chen, J. J., Cohen, G. H., Eisenberg, R. J., Belshe, R. B. & other authors (2007). Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis 196, 220-229.
13. Lehmann, E. L. (1975). Nonparametrics: Statistical Methods Based On Ranks. San Francisco: Holden-Day Inc.
14. Meyer, H., Sutter, G. & Mayr, A. (1991). Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72, 1031-1038.
15. Newman, F. K., Frey, S. E., Blevins, T. P., Mandava, M., Bonifacio, A., Jr, Yan, L. & Belshe, R. B. (2003). Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol 41, 3154-3157.
16. Panchanathan, V., Chaudhri, G. & Karupiah, G. (2008). Correlates of protective immunity in poxvirus infection: where does antibody stand? Immunol Cell Biol 86, 80-86.
17. Pütz, M. M., Alberini, I., Midgley, C. M., Manini, I., Montomoli, E. & Smith, G. L. (2005). Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy. J Gen Virol 86, 2955-2960.
18. Pütz, M. M., Midgley, C. M., Law, M. & Smith, G. L. (2006). Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12, 1310-1315.
19. Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H. C., Schafer, H. & Holzner, A. (1974). MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 99, 2386-2392 (in German).
20. + T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201, 95-104.
21. Viner, K. M. & Isaacs, S. N. (2005). Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect 7, 579-583.
22. Vollmar, J., Arndtz, N., Eckl, K. M., Thomsen, T., Petzold, B., Mateo, L., Schlereth, B., Handley, A., King, L. & other authors (2006). Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24, 2065-2070.